nodes	percent_of_prediction	percent_of_DWPC	metapath
Carfilzomib—PSMB10—adipose tissue—polycystic ovary syndrome	0.0149	0.0429	CbGeAlD
Carfilzomib—PSMB10—adrenal gland—polycystic ovary syndrome	0.0134	0.0385	CbGeAlD
Carfilzomib—PSMB10—female gonad—polycystic ovary syndrome	0.0125	0.0359	CbGeAlD
Carfilzomib—PSMB8—adrenal cortex—polycystic ovary syndrome	0.0119	0.0343	CbGeAlD
Carfilzomib—PSMB10—endocrine gland—polycystic ovary syndrome	0.0116	0.0334	CbGeAlD
Carfilzomib—PSMB1—embryo—polycystic ovary syndrome	0.0112	0.0324	CbGeAlD
Carfilzomib—PSMB2—embryo—polycystic ovary syndrome	0.011	0.0316	CbGeAlD
Carfilzomib—PSMB8—endometrium—polycystic ovary syndrome	0.0107	0.0307	CbGeAlD
Carfilzomib—PSMB5—adrenal cortex—polycystic ovary syndrome	0.0105	0.0303	CbGeAlD
Carfilzomib—PSMB8—pituitary gland—polycystic ovary syndrome	0.00965	0.0278	CbGeAlD
Carfilzomib—PSMB8—adipose tissue—polycystic ovary syndrome	0.00961	0.0276	CbGeAlD
Carfilzomib—PSMB5—endometrium—polycystic ovary syndrome	0.00942	0.0271	CbGeAlD
Carfilzomib—PSMB1—adrenal cortex—polycystic ovary syndrome	0.00922	0.0265	CbGeAlD
Carfilzomib—PSMB2—adrenal cortex—polycystic ovary syndrome	0.00899	0.0259	CbGeAlD
Carfilzomib—PSMB5—uterus—polycystic ovary syndrome	0.00868	0.025	CbGeAlD
Carfilzomib—PSMB8—adrenal gland—polycystic ovary syndrome	0.00862	0.0248	CbGeAlD
Carfilzomib—PSMB5—pituitary gland—polycystic ovary syndrome	0.00852	0.0245	CbGeAlD
Carfilzomib—PSMB5—adipose tissue—polycystic ovary syndrome	0.00849	0.0244	CbGeAlD
Carfilzomib—PSMB1—endometrium—polycystic ovary syndrome	0.00823	0.0237	CbGeAlD
Carfilzomib—PSMB8—female gonad—polycystic ovary syndrome	0.00804	0.0231	CbGeAlD
Carfilzomib—PSMB2—endometrium—polycystic ovary syndrome	0.00803	0.0231	CbGeAlD
Carfilzomib—PSMB8—vagina—polycystic ovary syndrome	0.00799	0.023	CbGeAlD
Carfilzomib—PSMB5—adrenal gland—polycystic ovary syndrome	0.00761	0.0219	CbGeAlD
Carfilzomib—PSMB1—uterus—polycystic ovary syndrome	0.00759	0.0218	CbGeAlD
Carfilzomib—PSMB1—pituitary gland—polycystic ovary syndrome	0.00745	0.0214	CbGeAlD
Carfilzomib—PSMB1—adipose tissue—polycystic ovary syndrome	0.00742	0.0213	CbGeAlD
Carfilzomib—PSMB2—uterus—polycystic ovary syndrome	0.0074	0.0213	CbGeAlD
Carfilzomib—PSMB2—pituitary gland—polycystic ovary syndrome	0.00727	0.0209	CbGeAlD
Carfilzomib—PSMB2—adipose tissue—polycystic ovary syndrome	0.00724	0.0208	CbGeAlD
Carfilzomib—PSMB5—female gonad—polycystic ovary syndrome	0.0071	0.0204	CbGeAlD
Carfilzomib—PSMB5—vagina—polycystic ovary syndrome	0.00706	0.0203	CbGeAlD
Carfilzomib—PSMB1—adrenal gland—polycystic ovary syndrome	0.00665	0.0191	CbGeAlD
Carfilzomib—PSMB2—adrenal gland—polycystic ovary syndrome	0.00649	0.0187	CbGeAlD
Carfilzomib—PSMB1—female gonad—polycystic ovary syndrome	0.0062	0.0178	CbGeAlD
Carfilzomib—PSMB1—vagina—polycystic ovary syndrome	0.00617	0.0177	CbGeAlD
Carfilzomib—PSMB2—female gonad—polycystic ovary syndrome	0.00605	0.0174	CbGeAlD
Carfilzomib—PSMB2—vagina—polycystic ovary syndrome	0.00602	0.0173	CbGeAlD
Carfilzomib—PSMB1—endocrine gland—polycystic ovary syndrome	0.00577	0.0166	CbGeAlD
Carfilzomib—PSMB2—endocrine gland—polycystic ovary syndrome	0.00563	0.0162	CbGeAlD
Carfilzomib—ABCB1—embryo—polycystic ovary syndrome	0.00168	0.00482	CbGeAlD
Carfilzomib—ABCB1—adrenal cortex—polycystic ovary syndrome	0.00137	0.00395	CbGeAlD
Carfilzomib—ABCB1—endometrium—polycystic ovary syndrome	0.00123	0.00353	CbGeAlD
Carfilzomib—ABCB1—uterus—polycystic ovary syndrome	0.00113	0.00325	CbGeAlD
Carfilzomib—ABCB1—pituitary gland—polycystic ovary syndrome	0.00111	0.00319	CbGeAlD
Carfilzomib—ABCB1—adipose tissue—polycystic ovary syndrome	0.00111	0.00318	CbGeAlD
Carfilzomib—ABCB1—adrenal gland—polycystic ovary syndrome	0.000992	0.00285	CbGeAlD
Carfilzomib—ABCB1—female gonad—polycystic ovary syndrome	0.000925	0.00266	CbGeAlD
Carfilzomib—ABCB1—vagina—polycystic ovary syndrome	0.000919	0.00264	CbGeAlD
Carfilzomib—ABCB1—endocrine gland—polycystic ovary syndrome	0.00086	0.00247	CbGeAlD
Carfilzomib—PSMB8—Disease—NRG1—polycystic ovary syndrome	6.65e-05	0.000102	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—AKT2—polycystic ovary syndrome	6.64e-05	0.000102	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—GNAS—polycystic ovary syndrome	6.64e-05	0.000102	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—IRS1—polycystic ovary syndrome	6.62e-05	0.000102	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—PLAT—polycystic ovary syndrome	6.58e-05	0.000101	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—PLAT—polycystic ovary syndrome	6.58e-05	0.000101	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—GHRL—polycystic ovary syndrome	6.58e-05	0.000101	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—GHRL—polycystic ovary syndrome	6.58e-05	0.000101	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—PLAT—polycystic ovary syndrome	6.58e-05	0.000101	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—GHRL—polycystic ovary syndrome	6.58e-05	0.000101	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—PLAT—polycystic ovary syndrome	6.49e-05	9.95e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—GHRL—polycystic ovary syndrome	6.49e-05	9.95e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—INS—polycystic ovary syndrome	6.37e-05	9.77e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—NCOR1—polycystic ovary syndrome	6.35e-05	9.74e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—INS—polycystic ovary syndrome	6.34e-05	9.73e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—NCOR1—polycystic ovary syndrome	6.32e-05	9.69e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Gene Expression—SERPINE1—polycystic ovary syndrome	6.31e-05	9.67e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—ATF1—polycystic ovary syndrome	6.28e-05	9.63e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—ATF1—polycystic ovary syndrome	6.28e-05	9.63e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—ATF1—polycystic ovary syndrome	6.28e-05	9.63e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Gene Expression—SERPINE1—polycystic ovary syndrome	6.28e-05	9.62e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—IRS2—polycystic ovary syndrome	6.26e-05	9.59e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—IRS2—polycystic ovary syndrome	6.26e-05	9.59e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—IRS2—polycystic ovary syndrome	6.26e-05	9.59e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—CRP—polycystic ovary syndrome	6.26e-05	9.59e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—CRP—polycystic ovary syndrome	6.26e-05	9.59e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—CRP—polycystic ovary syndrome	6.26e-05	9.59e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—NRG1—polycystic ovary syndrome	6.23e-05	9.56e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—NRG1—polycystic ovary syndrome	6.2e-05	9.51e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—ATF1—polycystic ovary syndrome	6.19e-05	9.49e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—polycystic ovary syndrome	6.19e-05	9.49e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—CRP—polycystic ovary syndrome	6.17e-05	9.46e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—IRS2—polycystic ovary syndrome	6.17e-05	9.46e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—AKT2—polycystic ovary syndrome	6.16e-05	9.45e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—AKT2—polycystic ovary syndrome	6.13e-05	9.4e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—TCF7L2—polycystic ovary syndrome	6.12e-05	9.39e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—TCF7L2—polycystic ovary syndrome	6.12e-05	9.39e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—TCF7L2—polycystic ovary syndrome	6.12e-05	9.39e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—MTHFR—polycystic ovary syndrome	6.07e-05	9.31e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—MTHFR—polycystic ovary syndrome	6.07e-05	9.31e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—MTHFR—polycystic ovary syndrome	6.07e-05	9.31e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—GNAS—polycystic ovary syndrome	6.04e-05	9.26e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—GNAS—polycystic ovary syndrome	6.04e-05	9.26e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—GNAS—polycystic ovary syndrome	6.04e-05	9.26e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—TCF7L2—polycystic ovary syndrome	6.04e-05	9.26e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—MTHFR—polycystic ovary syndrome	5.99e-05	9.18e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—AKR1C2—polycystic ovary syndrome	5.97e-05	9.15e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—TEAD2—polycystic ovary syndrome	5.97e-05	9.15e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—GNAS—polycystic ovary syndrome	5.96e-05	9.13e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—SERPINE1—polycystic ovary syndrome	5.86e-05	8.98e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—BCL2—polycystic ovary syndrome	5.83e-05	8.94e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—SERPINE1—polycystic ovary syndrome	5.83e-05	8.93e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—BCL2—polycystic ovary syndrome	5.8e-05	8.89e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—NGFR—polycystic ovary syndrome	5.8e-05	8.88e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—NGFR—polycystic ovary syndrome	5.8e-05	8.88e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—NGFR—polycystic ovary syndrome	5.8e-05	8.88e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—IRS2—polycystic ovary syndrome	5.78e-05	8.86e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—IRS2—polycystic ovary syndrome	5.78e-05	8.86e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—IRS2—polycystic ovary syndrome	5.78e-05	8.86e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—NCOR1—polycystic ovary syndrome	5.76e-05	8.82e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—NCOR1—polycystic ovary syndrome	5.76e-05	8.82e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—NCOR1—polycystic ovary syndrome	5.76e-05	8.82e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—PRL—polycystic ovary syndrome	5.74e-05	8.8e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—PRL—polycystic ovary syndrome	5.74e-05	8.8e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—PRL—polycystic ovary syndrome	5.74e-05	8.8e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—NGFR—polycystic ovary syndrome	5.71e-05	8.76e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—IRS2—polycystic ovary syndrome	5.7e-05	8.73e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—NCOR1—polycystic ovary syndrome	5.67e-05	8.7e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—PRL—polycystic ovary syndrome	5.66e-05	8.68e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—IRS1—polycystic ovary syndrome	5.46e-05	8.38e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—IRS1—polycystic ovary syndrome	5.46e-05	8.38e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—IRS1—polycystic ovary syndrome	5.46e-05	8.38e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—CYP1A1—polycystic ovary syndrome	5.46e-05	8.36e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—CYP1A1—polycystic ovary syndrome	5.46e-05	8.36e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—CYP1A1—polycystic ovary syndrome	5.46e-05	8.36e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—ADRB2—polycystic ovary syndrome	5.45e-05	8.35e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—ADRB2—polycystic ovary syndrome	5.45e-05	8.35e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—ADRB2—polycystic ovary syndrome	5.45e-05	8.35e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Metabolism—PPARG—polycystic ovary syndrome	5.44e-05	8.34e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—PPARG—polycystic ovary syndrome	5.42e-05	8.3e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—polycystic ovary syndrome	5.4e-05	8.28e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—IRS1—polycystic ovary syndrome	5.39e-05	8.26e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—CYP1A1—polycystic ovary syndrome	5.38e-05	8.25e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—ADRB2—polycystic ovary syndrome	5.37e-05	8.23e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Metabolism—POMC—polycystic ovary syndrome	5.37e-05	8.23e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—POMC—polycystic ovary syndrome	5.34e-05	8.19e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—IRS2—polycystic ovary syndrome	5.34e-05	8.19e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Metabolism—INS—polycystic ovary syndrome	5.34e-05	8.18e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Transmembrane transport of small molecules—TFRC—polycystic ovary syndrome	5.32e-05	8.15e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—IRS2—polycystic ovary syndrome	5.31e-05	8.15e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—INS—polycystic ovary syndrome	5.31e-05	8.14e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Gene Expression—PPARG—polycystic ovary syndrome	5.31e-05	8.13e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Gene Expression—PPARG—polycystic ovary syndrome	5.31e-05	8.13e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Gene Expression—PPARG—polycystic ovary syndrome	5.31e-05	8.13e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Gene Expression—PPARG—polycystic ovary syndrome	5.23e-05	8.02e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—LEP—polycystic ovary syndrome	5.23e-05	8.01e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—LEP—polycystic ovary syndrome	5.2e-05	7.97e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—MTHFR—polycystic ovary syndrome	5.09e-05	7.8e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—MTHFR—polycystic ovary syndrome	5.09e-05	7.8e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—MTHFR—polycystic ovary syndrome	5.09e-05	7.8e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—AKT2—polycystic ovary syndrome	5.06e-05	7.75e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—AKT2—polycystic ovary syndrome	5.06e-05	7.75e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—AKT2—polycystic ovary syndrome	5.06e-05	7.75e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—GNAS—polycystic ovary syndrome	5.05e-05	7.75e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—GNAS—polycystic ovary syndrome	5.05e-05	7.75e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—GNAS—polycystic ovary syndrome	5.05e-05	7.75e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—IRS1—polycystic ovary syndrome	5.04e-05	7.73e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—IRS1—polycystic ovary syndrome	5.04e-05	7.73e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—IRS1—polycystic ovary syndrome	5.04e-05	7.73e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—MTHFR—polycystic ovary syndrome	5.02e-05	7.69e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PNPLA2—polycystic ovary syndrome	5e-05	7.67e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—AKT2—polycystic ovary syndrome	4.99e-05	7.64e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—GNAS—polycystic ovary syndrome	4.98e-05	7.64e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—IRS1—polycystic ovary syndrome	4.97e-05	7.62e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Transmembrane transport of small molecules—PLAT—polycystic ovary syndrome	4.94e-05	7.58e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—INS—polycystic ovary syndrome	4.83e-05	7.41e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—INS—polycystic ovary syndrome	4.83e-05	7.41e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—INS—polycystic ovary syndrome	4.83e-05	7.41e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—NCOR1—polycystic ovary syndrome	4.81e-05	7.38e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—NCOR1—polycystic ovary syndrome	4.81e-05	7.38e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—NCOR1—polycystic ovary syndrome	4.81e-05	7.38e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Gene Expression—SERPINE1—polycystic ovary syndrome	4.78e-05	7.33e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Gene Expression—SERPINE1—polycystic ovary syndrome	4.78e-05	7.33e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Gene Expression—SERPINE1—polycystic ovary syndrome	4.78e-05	7.33e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—INS—polycystic ovary syndrome	4.76e-05	7.3e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—NCOR1—polycystic ovary syndrome	4.75e-05	7.27e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—SRD5A1—polycystic ovary syndrome	4.74e-05	7.27e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—NRG1—polycystic ovary syndrome	4.72e-05	7.24e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—NRG1—polycystic ovary syndrome	4.72e-05	7.24e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—NRG1—polycystic ovary syndrome	4.72e-05	7.24e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Gene Expression—SERPINE1—polycystic ovary syndrome	4.71e-05	7.22e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—AKT2—polycystic ovary syndrome	4.67e-05	7.16e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—AKT2—polycystic ovary syndrome	4.67e-05	7.16e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—AKT2—polycystic ovary syndrome	4.67e-05	7.16e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—IRS1—polycystic ovary syndrome	4.66e-05	7.15e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—NRG1—polycystic ovary syndrome	4.66e-05	7.14e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—IRS1—polycystic ovary syndrome	4.64e-05	7.11e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—AKT2—polycystic ovary syndrome	4.6e-05	7.06e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—STAR—polycystic ovary syndrome	4.52e-05	6.94e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Transmembrane transport of small molecules—SLC2A4—polycystic ovary syndrome	4.52e-05	6.93e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—POMC—polycystic ovary syndrome	4.49e-05	6.88e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—POMC—polycystic ovary syndrome	4.47e-05	6.85e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—INS—polycystic ovary syndrome	4.46e-05	6.84e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—INS—polycystic ovary syndrome	4.44e-05	6.81e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—SERPINE1—polycystic ovary syndrome	4.44e-05	6.8e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—SERPINE1—polycystic ovary syndrome	4.44e-05	6.8e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—SERPINE1—polycystic ovary syndrome	4.44e-05	6.8e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—BCL2—polycystic ovary syndrome	4.42e-05	6.77e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—BCL2—polycystic ovary syndrome	4.42e-05	6.77e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—BCL2—polycystic ovary syndrome	4.42e-05	6.77e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—SERPINE1—polycystic ovary syndrome	4.37e-05	6.71e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—BCL2—polycystic ovary syndrome	4.36e-05	6.68e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—IGF1—polycystic ovary syndrome	4.32e-05	6.62e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—AKT2—polycystic ovary syndrome	4.31e-05	6.61e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—IGF1—polycystic ovary syndrome	4.3e-05	6.59e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—AKT2—polycystic ovary syndrome	4.29e-05	6.58e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—PPARG—polycystic ovary syndrome	4.13e-05	6.32e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—PPARG—polycystic ovary syndrome	4.13e-05	6.32e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—PPARG—polycystic ovary syndrome	4.13e-05	6.32e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—SERPINE1—polycystic ovary syndrome	4.1e-05	6.29e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—SERPINE1—polycystic ovary syndrome	4.08e-05	6.26e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—POMC—polycystic ovary syndrome	4.07e-05	6.24e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—POMC—polycystic ovary syndrome	4.07e-05	6.24e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—POMC—polycystic ovary syndrome	4.07e-05	6.24e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—PPARG—polycystic ovary syndrome	4.07e-05	6.23e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—IRS2—polycystic ovary syndrome	4.05e-05	6.2e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—IRS2—polycystic ovary syndrome	4.05e-05	6.2e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—IRS2—polycystic ovary syndrome	4.05e-05	6.2e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—INS—polycystic ovary syndrome	4.05e-05	6.2e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—INS—polycystic ovary syndrome	4.05e-05	6.2e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—INS—polycystic ovary syndrome	4.05e-05	6.2e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—polycystic ovary syndrome	4.04e-05	6.2e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—HMMR—polycystic ovary syndrome	4.03e-05	6.18e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—POMC—polycystic ovary syndrome	4.01e-05	6.15e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—IRS2—polycystic ovary syndrome	3.99e-05	6.12e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—INS—polycystic ovary syndrome	3.99e-05	6.11e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—LEP—polycystic ovary syndrome	3.96e-05	6.07e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—LEP—polycystic ovary syndrome	3.96e-05	6.07e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—LEP—polycystic ovary syndrome	3.96e-05	6.07e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—LEP—polycystic ovary syndrome	3.9e-05	5.98e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—HSD3B1—polycystic ovary syndrome	3.85e-05	5.9e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Transmembrane transport of small molecules—GNAS—polycystic ovary syndrome	3.8e-05	5.82e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—IRS1—polycystic ovary syndrome	3.53e-05	5.42e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—IRS1—polycystic ovary syndrome	3.53e-05	5.42e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—IRS1—polycystic ovary syndrome	3.53e-05	5.42e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—LHB—polycystic ovary syndrome	3.51e-05	5.38e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—IRS1—polycystic ovary syndrome	3.48e-05	5.34e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—HSD3B2—polycystic ovary syndrome	3.43e-05	5.26e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—POMC—polycystic ovary syndrome	3.4e-05	5.21e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—POMC—polycystic ovary syndrome	3.4e-05	5.21e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—POMC—polycystic ovary syndrome	3.4e-05	5.21e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—INS—polycystic ovary syndrome	3.38e-05	5.19e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—INS—polycystic ovary syndrome	3.38e-05	5.19e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—INS—polycystic ovary syndrome	3.38e-05	5.19e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—POMC—polycystic ovary syndrome	3.35e-05	5.14e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—INS—polycystic ovary syndrome	3.34e-05	5.11e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—AKR1C1—polycystic ovary syndrome	3.32e-05	5.09e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—IGF1—polycystic ovary syndrome	3.27e-05	5.02e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—IGF1—polycystic ovary syndrome	3.27e-05	5.02e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—IGF1—polycystic ovary syndrome	3.27e-05	5.02e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—AKT2—polycystic ovary syndrome	3.27e-05	5.01e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—AKT2—polycystic ovary syndrome	3.27e-05	5.01e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—AKT2—polycystic ovary syndrome	3.27e-05	5.01e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—IGF1—polycystic ovary syndrome	3.23e-05	4.95e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—AKT2—polycystic ovary syndrome	3.22e-05	4.94e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.11e-05	4.76e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.11e-05	4.76e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.11e-05	4.76e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.06e-05	4.7e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—SULT2A1—polycystic ovary syndrome	3.06e-05	4.68e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—IL6—polycystic ovary syndrome	3.02e-05	4.62e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—IL6—polycystic ovary syndrome	3e-05	4.6e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—RRM2—polycystic ovary syndrome	2.96e-05	4.54e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—YAP1—polycystic ovary syndrome	2.85e-05	4.37e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.82e-05	4.32e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.81e-05	4.3e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—IL6—polycystic ovary syndrome	2.79e-05	4.27e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—IL6—polycystic ovary syndrome	2.77e-05	4.25e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—NAMPT—polycystic ovary syndrome	2.74e-05	4.2e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CYP11A1—polycystic ovary syndrome	2.71e-05	4.15e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—AKR1C3—polycystic ovary syndrome	2.56e-05	3.92e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CYP17A1—polycystic ovary syndrome	2.52e-05	3.86e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—IL6—polycystic ovary syndrome	2.29e-05	3.5e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—IL6—polycystic ovary syndrome	2.29e-05	3.5e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—IL6—polycystic ovary syndrome	2.29e-05	3.5e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—IL6—polycystic ovary syndrome	2.25e-05	3.46e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—TH—polycystic ovary syndrome	2.18e-05	3.34e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.14e-05	3.28e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.14e-05	3.28e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.14e-05	3.28e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—SLC2A4—polycystic ovary syndrome	2.12e-05	3.25e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—IL6—polycystic ovary syndrome	2.11e-05	3.24e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—IL6—polycystic ovary syndrome	2.11e-05	3.24e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—IL6—polycystic ovary syndrome	2.11e-05	3.24e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.11e-05	3.23e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—IL6—polycystic ovary syndrome	2.08e-05	3.19e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CYP19A1—polycystic ovary syndrome	1.99e-05	3.05e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—IL6—polycystic ovary syndrome	1.95e-05	2.99e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—IL6—polycystic ovary syndrome	1.94e-05	2.98e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—GNAS—polycystic ovary syndrome	1.78e-05	2.73e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—NCOR1—polycystic ovary syndrome	1.69e-05	2.6e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CYP1A1—polycystic ovary syndrome	1.61e-05	2.46e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—MTHFR—polycystic ovary syndrome	1.5e-05	2.29e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—IL6—polycystic ovary syndrome	1.48e-05	2.27e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—IL6—polycystic ovary syndrome	1.48e-05	2.27e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—IL6—polycystic ovary syndrome	1.48e-05	2.27e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—IL6—polycystic ovary syndrome	1.46e-05	2.23e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PPARG—polycystic ovary syndrome	1.21e-05	1.86e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—POMC—polycystic ovary syndrome	1.2e-05	1.83e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—INS—polycystic ovary syndrome	1.19e-05	1.82e-05	CbGpPWpGaD
